SV

Sinovac Biotech LtdNASDAQ SVA Stock Report

Last reporting period 30 Jun, 2023

Updated 11 Nov, 2024

Last price

Market cap $B

0.122

Micro

Exchange

XNAS - Nasdaq

SVA Stock Analysis

SV

Uncovered

Sinovac Biotech Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-16/100

Low score

Market cap $B

0.122

Dividend yield

Shares outstanding

99.5 B

Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company is headquartered in Beijing, Beijing and currently employs 4,281 full-time employees. The company went IPO on 2009-11-13. The firm is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The firm's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The firm is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The firm develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

View Section: Eyestock Rating